Abstract: A fusion nanoprotein is provided wherein TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment and exhibits enhanced cancer targeting using a cancer-targeting peptide. The fusion protein effectively targets cancer cells when injected into a blood vessel, leading to TRAIL-induced cancer cell death. This fusion nanoprotein addresses key challenges of TRAIL proteins by improving their stability and reducing off-target effects through stable delivery of TRAIL trimers specifically to cancer tissues. The enhanced stability and targeted delivery properties make this fusion protein a promising candidate for development as an anticancer therapeutic agent.

Abstract: The present disclosure is directed toward drugs or toxins; drug conjugates comprising said drugs or toxins and a cleavable linker; and conjugates comprising said drugs or toxins, cleavable linkers, and cell-binding groups. The present disclosure also relates to methods of treating cancers, autoimmune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

Abstract: The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC (SEQ ID NO: 2)) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1.

Abstract: The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto-immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

Abstract: The present invention relates to a ferritin nanocage for multi-displaying a TRAIL trimer and a cancer-targeting peptide, and use thereof as an anticancer agent, and relates to the development of a TRAIL fusion nanoprotein, in which TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment, and which exhibits enhanced cancer targeting using a cancer-targeting peptide. When injected into a blood vessel, the fusion protein according to the present invention effectively targets cancer and thus effectively leads to cancer death caused by TRAIL, wherein the fusion nanoprotein addresses the instability and off-targeting problems of TRAIL proteins, stably delivers a TRAIL trimer to cancer tissue, and thus there is a high possibility of developing an anticancer agent using same.